Search: onr:"swepub:oai:gup.ub.gu.se/335561" >
Impact of BMI in Pa...
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
- Article/chapterEnglish2023
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/335561
-
https://gup.ub.gu.se/publication/335561URI
-
https://doi.org/10.1200/JCO.23.00126DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:237556775URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:154966939URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
PURPOSEBMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib.METHODSPatients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived.RESULTSOf 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months).CONCLUSIONThis preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome. This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Hlauschek, Dominik
(author)
-
Mayer, Erica L.
(author)
-
Deutschmann, Christine
(author)
-
Kacerovsky-Strobl, Stephanie
(author)
-
Martin, Miguel
(author)
-
Meisel, Jane Lowe
(author)
-
Zdenkowski, Nicholas
(author)
-
Loibl, Sibylle
(author)
-
Balic, Marija
(author)
-
Park, Haeseong
(author)
-
Prat, Aleix
(author)
-
Isaacs, Claudine
(author)
-
Bajetta, Emilio
(author)
-
Balko, Justin M.
(author)
-
Bellet-Ezquerra, Merixtell
(author)
-
Bliss, Judith
(author)
-
Burstein, Harold
(author)
-
Cardoso, Fatima
(author)
-
Fohler, Hannes
(author)
-
Foukakis, TheodorosKarolinska Institutet
(author)
-
Gelmon, Karen A.
(author)
-
Goetz, Matthew
(author)
-
Haddad, Tufia C.
(author)
-
Iwata, Hiroji
(author)
-
Jassem, Jacek
(author)
-
Lee, Soo-Chin
(author)
-
Linderholm, Barbro,1959Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xlibar
(author)
-
Los, Maartje
(author)
-
Mamounas, Eleftherios P.
(author)
-
Miller, Kathy D.
(author)
-
Morris, Patrick G.
(author)
-
Munzone, Elisabetta
(author)
-
Gal-Yam, Einav Nili
(author)
-
Ring, Alistair
(author)
-
Shepherd, Lois
(author)
-
Singer, Christian
(author)
-
Thomssen, Christoph
(author)
-
Tseng, Ling-Ming
(author)
-
Valagussa, Pinuccia
(author)
-
Winer, Eric P.
(author)
-
Wolff, Antonio C.
(author)
-
Zoppoli, Gabriele
(author)
-
Machacek-Link, Jana
(author)
-
Schurmans, Celine
(author)
-
Huang, Xin
(author)
-
Gauthier, Eric
(author)
-
Fesl, Christian
(author)
-
Dueck, Amylou C.
(author)
-
DeMichele, Angela
(author)
-
Gnant, Michael
(author)
-
Karolinska InstitutetInstitutionen för kliniska vetenskaper, Avdelningen för onkologi
(creator_code:org_t)
Related titles
-
In:JOURNAL OF CLINICAL ONCOLOGY41:330732-183X1527-7755
Internet link
Find in a library
To the university's database
- By the author/editor
-
Pfeiler, Georg
-
Hlauschek, Domin ...
-
Mayer, Erica L.
-
Deutschmann, Chr ...
-
Kacerovsky-Strob ...
-
Martin, Miguel
-
show more...
-
Meisel, Jane Low ...
-
Zdenkowski, Nich ...
-
Loibl, Sibylle
-
Balic, Marija
-
Park, Haeseong
-
Prat, Aleix
-
Isaacs, Claudine
-
Bajetta, Emilio
-
Balko, Justin M.
-
Bellet-Ezquerra, ...
-
Bliss, Judith
-
Burstein, Harold
-
Cardoso, Fatima
-
Fohler, Hannes
-
Foukakis, Theodo ...
-
Gelmon, Karen A.
-
Goetz, Matthew
-
Haddad, Tufia C.
-
Iwata, Hiroji
-
Jassem, Jacek
-
Lee, Soo-Chin
-
Linderholm, Barb ...
-
Los, Maartje
-
Mamounas, Elefth ...
-
Miller, Kathy D.
-
Morris, Patrick ...
-
Munzone, Elisabe ...
-
Gal-Yam, Einav N ...
-
Ring, Alistair
-
Shepherd, Lois
-
Singer, Christia ...
-
Thomssen, Christ ...
-
Tseng, Ling-Ming
-
Valagussa, Pinuc ...
-
Winer, Eric P.
-
Wolff, Antonio C ...
-
Zoppoli, Gabriel ...
-
Machacek-Link, J ...
-
Schurmans, Celin ...
-
Huang, Xin
-
Gauthier, Eric
-
Fesl, Christian
-
Dueck, Amylou C.
-
DeMichele, Angel ...
-
Gnant, Michael
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
JOURNAL OF CLINI ...
- By the university
-
University of Gothenburg
-
Karolinska Institutet